CD ComputaBio and AtomBeat Announce Strategic Partnership to Revolutionize Virtual Drug Design and Peptide Discovery
NEW YORK, NY — CD ComputaBio, a premium provider of computational biology services, is pleased to announce it has entered into a formal strategic cooperation agreement with AtomBeat, a pioneer in AI-driven molecular dynamics and in silico modeling. This partnership aims to integrate CD ComputaBio’s extensive service portfolio with AtomBeat’s cutting-edge computational platforms to accelerate the discovery and design of novel therapeutic candidates.
The collaboration will focus on the practical application of virtual drug design, specifically leveraging AtomBeat’s proprietary software suites, such as Hermite and RiDYMO, alongside CD ComputaBio’s expertise in molecular docking and molecular dynamics (MD) simulations. By combining these capabilities, the two companies will provide an end-to-end solution for screening vast chemical libraries and optimizing drug-target interactions with unprecedented speed and accuracy.
"Our partnership with AtomBeat represents a significant leap forward in our mission to provide high-performance computational solutions," said the spokesperson for CD ComputaBio. "By merging our service-oriented approach with AtomBeat's advanced AI algorithms, we are helping researchers navigate the 'valley of death' in drug discovery more efficiently than ever before."
The joint venture is expected to significantly reduce the R&D cycle for pharmaceutical clients by identifying high-affinity "hits" in a virtual environment before moving to costly wet-lab validation.
About CD ComputaBio
CD ComputaBio is a leading computational biology service provider, offering a wide range of services including molecular dynamics simulation, drug design, virtual screening, and quantum chemical calculations to the global pharmaceutical and biotech industries.
About AtomBeat
AtomBeat specializes in AI-accelerated drug discovery, utilizing reinforced dynamics and advanced modeling to explore chemical space and optimize complex therapeutic modalities, including cyclic peptides and small molecules.
Related News
